Alphatec Holdings ATEC

David M Demski (Director) bought 60,000 ATEC at $6.81, worth $409K

Form: 4
Filed: Nov 2, 2026, 12:23 pm ET
Importance: Major
Accession: 0001555392-26-000004

David M Demski bought 60,000 shares at $6.81
Total shares owned: 491,635
Transaction was part of a pre-planned trading plan

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the app Get the app View on EDGAR

The reading, claim by claim

The filing includes details about David M.
Demski, who is listed as a director and 10% owner of the company.
The form indicates a transaction on October 30, 2026, involving common stock.
The form also notes that the transaction may have been part of a contract, instruction, or written plan for the purchase or sale of equity securities.

4 of 6 claims matched the filing text.

Not found in the filing text

Alphatec Holdings, Inc. filed a Form 4 on November 2, 2026, reporting changes in beneficial ownership.
The filing shows that Demski had a transaction involving common stock, but it does not specify the number of shares or the price.

For perspective, checked against its own source

From the 10-Q for the quarter ended September 30, 2026

For the quarter ended September 30, 2026, Alphatec reported revenue of $221.2 million and a net loss of $5.5 million.
The company's gross margin was 71.5%, with an operating margin of 1.5% and a net margin of -2.5%.
Revenue increased by 12.6% compared to the same period last year.

From the filing

Filing text

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

X⁴

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).⁴ See Instruction 10.

1.¹ ¹Name and Address of Reporting Person * Demski David M¹

(Last) (First) (Middle)

C/O ALPHATEC SPINE, INC.

1950 CAMINO VIDA ROBLE

(Street) CARLSBAD

CALIFORNIA

92008

(City) (State) (Zip)

UNITED STATES

(Country) 2. Issuer Name and Ticker or Trading Symbol

Alphatec Holdings, Inc.

[ ATEC ]

5.² ²Relationship of Reporting Person(s) to Issuer²

(Check all applicable) X Director 10% Owner²

Officer (give title below) Other (specify below)

2a. Foreign Trading Symbol

3.³ ³Date of Earliest Transaction³

(Month/Day/Year)³

10/30/2026³ 6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed

(Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

2. Transaction Date

(Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr.

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

7. Nature of Indirect Beneficial Ownership (Instr.

Code V Amount (A) or (D) Price³

Common Stock 10/30/2³

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

Tandem Diabetes Care TNDM public float $1.3B, Jun 30, 2025
Artivion AORT public float $1.4B, Jun 30, 2025
CONMED CNMD public float $1.2B, Jun 30, 2025
AtriCure ATRC public float $1.6B, Jun 30, 2025
NovoCure NVCR public float $995M, Jun 30, 2025